Clinical Trial

Lithium for Parkinson's: an Extension Trial

Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-08; most recent amendment 2025-11-18.
Trial Details
NCT Number NCT06592014
Lead Sponsor State University of New York at Buffalo
Conditions Parkinson Disease
Enrollment 35 participants
Start Date 2024-08-09
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-19